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A B S T R A C T
The gastrin-releasing peptide receptor (GRPr) is overexpressed in>75% of breast cancers. 177Lu-Bombesin
(177Lu-BN) has demonstrated the ability to target GRPr and facilitate efficient delivery of therapeutic radiation
doses to malignant cells. Poly(D,L‑lactide‑co‑glycolide) acid (PLGA) nanoparticles can work as smart drug con-
trolled-release systems activated through pH changes. Considering that paclitaxel (PTX) is a first-line drug for
cancer treatment, this work aimed to synthesize and chemically characterize a novel polymeric PTX-loaded
nanosystem with grafted 177Lu-BN and to evaluate its performance as a targeted controlled-release nanomedi-
cine for concomitant radiotherapy and chemotherapy of breast cancer.
PLGA(PTX) nanoparticles were synthesized using the single emulsification-solvent evaporation method with
PVA as a stabilizer in the presence of PTX. Thereafter, the activation of PLGA carboxylic groups for BN at-
tachment through the Lys1-amine group was performed. Results of the chemical characterization by FT-IR, DLS,
HPLC and SEM/TEM demonstrated the successful synthesis of BN-PLGA(PTX) with a hydrodynamic diameter of
163.54 ± 33.25 nm. The entrapment efficiency of paclitaxel was 92.8 ± 3.6%. The nanosystem showed an
adequate controlled release of the anticancer drug, which increased significantly due to the pH change from
neutral (pH=7.4) to acidic conditions (pH=5.3). After labeling with 177Lu and purification by ultrafiltration,
177Lu-BN-PLGA(PTX) was obtained with a radiochemical purity of 99 ± 1%.
In vitro and in vivo studies using MDA-MB-231 breast cancer cells (GRPr-positive) demonstrated a 177Lu-BN-
PLGA(PTX) specific uptake and a significantly higher cytotoxic effect for the radiolabeled nanosystem than the
unlabeled BN-PLGA(PTX) nanoparticles. Using a pulmonary micrometastasis MDA-MB-231 model, the added
value of 177Lu-BN-PLGA(PTX) for tumor imaging was confirmed. The 177Lu-BN-PLGA(PTX) nanomedicine is
suitable as a targeted paclitaxel delivery system with concomitant radiotherapeutic effect for the treatment of
GRPr-positive breast cancer.
1. Introduction
Recently, nanoradiopharmaceuticals have received more attention
as suitable approaches for imaging and/or therapy for several cancer
types. Nanoparticles (NPs) offer useful platforms for the design of more
effective drug delivery systems. Moreover, NPs can be functionalized to
allow target-specific recognition towards receptors overexpressed in
malignant tissues. Particularly, polymeric nanoparticles have generated
special interest in the field of cancer treatment due to their ability to
encapsulate drugs and release them in a controlled manner [1]. Poly
lactic-co-glycolic acid (PLGA) is approved for human use as a smart
nanosystem for drug delivery due to its response to pH changes, bio-
compatibility and biodegradability [2,3]. Usually, a therapeutic agent is
dispersed throughout the polymeric matrix or can be encapsulated in
the hydrophobic nanoparticle core.
Paclitaxel (PTX) has become a first-line drug for the treatment of
solid cancers. However, its use is hampered by its toxicity, poor bioa-
vailability and severe side effects. Hence, the drug has been used as a
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model to evaluate and optimize drug delivery systems based on nano-
particles [4].
Bombesin (BN) is a homolog to the mammalian gastrin-releasing
peptide (GRP) and has demonstrated high sensitivity to detect the GRP
receptor (GRPr) in breast cancer [5]. Recently, a study of 1432 tumor
patients revealed that GRPr is overexpressed in 75.8% of several phe-
notypes of breast cancer and was also found in metastatic lymph nodes
in 94.6% of cases [6]. A variety of BN derivatives radiolabeled with
different radionuclides have been widely studied as targeting ligands
for diagnosis and/or therapy of GRPr-positive tumors [2,7]. Moreover,
BN can properly be attached to the surface of a nanoparticle to enhance
its affinity towards a desired molecular target [8–10]. Polymeric na-
noparticles functionalized with BN have been proposed as suitable drug
delivery systems [11,12].
Lutetium-177 (177Lu, half-life of 6.6 days) is a theranostic beta-
emitter (Emax of 498.3 keV), a feature that enables it to produce cyto-
toxicity towards tumors or metastatic lesions (particle range in tissue
around 2mm), and a gamma-emitter (Emax= 208 keV), which makes it
useful for imaging [5]. 177Lu-BN derivatives have been tested on pa-
tients with prostate cancer overexpressing GRPr and represent a useful
tool for diagnostic imaging and targeted radiotherapy [5,13].
Considering that paclitaxel (PTX) is a first-line drug for the treat-
ment of solid cancers and taking advantage of the therapeutic effect of
177Lu-Bombesin, this work aimed to prepare and evaluate a novel 177Lu-
labeled PTX-loaded nanocarrier grafted to Lys1Lys3(177Lu-DOTA)
Bombesin in breast cancer cells as a potential combined therapy system
for breast cancer.
2. Materials and methods
2.1. Materials
Paclitaxel (PTX), Poly(D,L‑lactide‑co‑glycolide) acid (50:50 MW
24,000–38,000 g/mol) and Poly(vinyl alcohol) (PVA; Mowiol®4-88)
were purchased from Sigma-Aldrich (St. Louis Missouri, USA). The
Lys1Lys3(DOTA)-Bombesin(1-14) peptide [Bombesin, BN] was obtained
from Bachem (Product 4097020) laboratory (Graz, Austria); lutetium-
177 (177Lu), as lutetium chloride (177LuCl3), was supplied by ITG
(Germany); dimethylformamide (DMF), N,N-diisopropylethylamine
(DIPEA), 2‑(1H‑7‑azabenzotriazol‑1‑yl)‑1.1.3.3‑tetramethyluronium‑
hexafluorophosphate (HATU) and all other reagents were analytical
grade. The XTT kit was obtained from Roche Diagnostics (Indianapolis,
IN. USA) and MDA-MB-231 cell line was obtained from ATCC (Atlanta,
GA, USA).
2.2. Preparation of PLGA nanoparticles
PLGA nanoparticles (hereafter denoted PLGA) were prepared using
the single emulsification-solvent evaporation method, employing PVA
as stabilizer [14]. Briefly, an organic solution of the Poly(D,L‑lacti-
de‑co‑glycolide) acid polymer (15mg/mL in acetone) and methanol
(1.32mL) was mixed and immediately added drop-wise onto a 0.25%
PVA solution (7.29mL) under ultra-sonication in an ice bath. After
10min, acetone/methanol were removed using a rotary vacuum eva-
porator (65 °C, 40 rpm, 20min). The obtained nano-suspension was
filtered and washed with injectable-grade water by ultracentrifugation
(MWCO 30 kDa, 2500g, 30min) and the pellet was freeze-dried for
24 h.
2.3. Preparation of paclitaxel-loaded nanoparticles
To prepare paclitaxel-loaded nanoparticles [PLGA(PTX)], the PLGA
polymer (15mg/mL in acetone) and 1mg of paclitaxel in acetone so-
lution were placed in magnetic stirring for 30min. Posteriorly, me-
thanol (1.32mL) was added. Then, the procedure mentioned above for
PLGA synthesis was applied (Fig. 1).
The non-incorporated drug was removed by ultracentrifugation
(MWCO 30 kDa, 2500g, 30min), and the purified nano-suspension ob-
tained was freeze-dried and stored for posterior use.
2.4. Bioconjugation of bombesin to polymeric nanoparticles
Lys1Lys3(DOTA)-Bombesin was conjugated to PLGA and PLGA(PTX)
NPs to prepare BN-PLGA or BN-PLGA(PTX) systems. Briefly, lyophilized
PLGA or PLGA(PTX) NPs (5mg) were dissolved in 50 μL of water and
100 μL of DMF; 100 μL of DIPEA solution (10 μL of DIPEA in 300 μL of
DMF) and the carboxylate-activating agent HATU (10mg in 100 μL of
DMF) were added. The mix was then exposed to sonication for 15min.
Lys1Lys3(DOTA)-BN (1mg/100 μL in DMF) was afterwards added, and
the mixture was incubated under slow stirring for 2 h at room tem-
perature (Fig. 1). The obtained nano-suspensions, BN-PLGA or BN-
PLGA(PTX), were purified by ultracentrifugation, as previously de-
scribed.
2.5. Radiolabeling
BN-PLGA and BN-PLGA(PTX) NPs were radiolabeled through the
DOTA bifunctional chelator on the Lys1Lys3(DOTA)-Bombesin structure
with 177Lu (Fig. 1). Radiolabeling was carried out by adding 177LuCl3
solution (10 μL, 148MBq) to the BN-PLGA or BN-PLGA(PTX) (500 μg in
40 μL of 0.25M acetate buffer, pH 7). Each mixture was then heated at
37 °C for 3 h. Nanoparticles were purified by ultracentrifugation
(MWCO 30 kDa, 2500g, 20min). Both fractions (filtered and unfiltered)
were measured in an activimeter (Capintec, USA) to calculate the
radiolabeling yield of 177Lu-BN-PLGA and 177Lu-BN-PLGA(PTX). To
evaluate the radiochemical purity, ITLC-SG strips (Pall Corporation)
were used as stationary phase and NaCl 0.9%/0.02M HCl, as mobile
phases. Free lutetium was identified at the solvent front (Rf= 1.0).
2.6. Physicochemical characterization
2.6.1. Hydrodynamic diameter and zeta potential
Adequate aqueous dilutions of the nanosystems [PLGA, PLGA(PTX),
BN-PLGA, BN-PLGA(PTX)] were used to measure particle size and zeta
potential through Dynamic Light Scattering (DLS) using a nanoparticle
size analyzer (Nanotrac Wave, Model MN401, Microtract, FL, USA). The
analysis was performed at a wavelength of 657 nm at 20 °C, current of
15.79mA, electric field of 14.35 V/cm and sampling time of 128 μs, in
triplicate.
2.6.2. Scanning electron microscopy (SEM) and transmission electron
microscopy (TEM)
Morphology of the obtained systems was examined through SEM. A
drop of each sample was placed on a metal slab, dried and coated with a
gold layer (Denton Vacuum DESK IV sputtering system, Moorestown,
NJ). The coated samples were scanned using an electron acceleration
voltage of 20–25 keV (JEOL JSM-5900 Low Vacuum, USA).
Additionally, systems were analyzed through TEM in a JEOL JEM
2010 HT microscope operating at 200 kV to observe the relative size
and morphology. Samples were prepared for analysis by evaporating a
drop of aqueous product on a carbon-coated TEM copper grid.
2.6.3. Infrared spectroscopy
The FT-IR measurements were performed on a PerkinElmer System
2000 spectrometer with an attenuated total reflection (ATR) platform
(Pike Technologies). The spectra were obtained from 50 scans at a
0.4 cm−1 resolution, from 400 to 4000 cm−1.
2.7. Entrapment efficiency
Drug analysis was carried out through high-performance liquid
chromatography (HPLC) using a reverse phase C18 column
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(μBondapak®, 10 μm 125A°, 3.9× 150mm) as the stationary phase and
acetonitrile:water (60:40 v/v) as the mobile phase. Separation was
carried out at a flow rate of 1mL/min, with a run time of 5min for each
sample. PTX was measured at 227 nm on a Waters Empower system
using a PTX calibration curve (r2 of 0.997, 6.0–300.0 μg/mL). The ex-
periments were conducted in triplicate.
The encapsulation efficiency (%EE) and drug loading (%DL) were
evaluated through HPLC analysis. The concentration of non-en-
capsulated PTX in the filtered solution was obtained from the ultra-
centrifugation process (MWCO 30 kDa, 2500g, 20min). These para-
meters, expressed as a percentage, were determined as follows:
= ×EE Mass of PTX in nanoparticles
Initial Mass of PTX
% 100
(1)




2.8. In vitro PTX release
For the in vitro drug release studies, a solution of phosphate-buffered
saline (PBS) containing 0.05% Tween-20, at pH 7.4 or pH 5.3, simu-
lating physiological pH or tumor microenvironment, respectively, was
used. Briefly, 10mg of PLGA(PTX) were dispersed in 1mL of release
medium and placed in a dialysis membrane (MWCO 30 kDa). The dia-
lysis bag was closed and immersed into a flask containing PBS (10mL)
at 37 °C and stirred at 110 rpm. At specified time points, an aliquot of
0.2 mL of the medium was collected and replaced with fresh PBS.
Released PTX was measured through HPLC based on the previously
described methodology [15].
2.9. Bombesin conjugation efficiency
Conjugation efficiency was determined by measuring free BN in the
filtered solution after ultracentrifugation. The reverse-phase HPLC
method was carried out using a C18 column (μBondapak® C18 10 μm
125A°, 3.9× 300mm) as a stationary phase and a gradient of water/
acetonitrile containing 0.1% TFA from 95/5 (v/v) to 20/80 (v/v) as the
mobile phase. Separation was carried out at a flow rate of 1mL/min
and a run time of 30min. A BN standard curve (r2= 0.999,
0.07–2.2 mg/mL) was used in this analysis.
2.10. In vitro studies
2.10.1. Cell lines
MDA-MB-231 human breast cancer cells (GRPr-positive) [5,16,17]
were originally obtained from the American Type Culture Collection
(USA). The cells were routinely grown at 37 °C, with 5% CO2 atmo-
sphere and 85% humidity in RPMI medium supplemented with 10%
newborn calf serum and antibiotics (100 μg/mL streptomycin, 100 U/
mL penicillin).
2.10.2. In vitro binding assay and non-specific binding
MDA-MB-231cells were harvested through trypsinization and
seeded in 24-well culture plates (1× 105 cells/well, 0.5 mL). After
24 h, the medium was removed and the cells were incubated with
adequate treatment dilution (177Lu-BN-PLGA(PTX) or 177Lu-BN,
equivalent to 50 kBq per well) for 45min at 37 °C. Each well was then
rinsed twice with PBS. To displace the membrane-bound radio-
pharmaceutical fraction, cells were incubated twice (5min, 37 °C) with
500 μL of 20mM Gly/HCl, and the activity of the total withdrawn vo-
lume was transferred to counting tubes. The cells were then incubated
twice with 500 μL of a 1M NaOH solution (5min, 37 °C); this fraction
(cytoplasm and nucleus) represented nanosystem internalization. The
total volume was transferred to counting tubes. Radioactivity in each
tube was measured in a gamma NaI(Tl) detector (NML Inc., USA). An
aliquot with the initial activity was measured as the radioactivity
standard in each treatment. The uptake percentage was calculated.
Non-specific binding (cells with blocked receptors) was determined in
parallel, in the presence of 5.7 μM Lys1Lys3(DOTA)-BN with 10min of
pre-incubation.
2.10.3. Cytotoxicity studies
To compare the cytotoxic effect produced by 177Lu-BN-PLGA(PTX),
different treatments (PLGA, PLGA(PTX), BN-PLGA, 177Lu-BN-
PLGA(PTX), PTX, 177Lu-BN) were evaluated in MDA-MB-231 cells,
mainly to compare the PTX contribution since the effect produced by
the β-emission of 177Lu is well-documented. A sublethal dose was used
to determine differences among treatments without the cell-killing ef-
fect. The concentration of nanosystems for radiolabeling was calculated
in terms of PTX content and adjusted to 1.5 μM to use one-tenth of the
lethal dose based on previous reports (breast cancer cells IC50= 15 μM
[18]).
The cytotoxic activity was measured using a Cell Proliferation Assay
(XTT) kit, according to the manufacturer's protocol (Roche Diagnostics
GmbH, Mannheim, Germany). Cells were seeded in a 96-well microtiter
plate (1× 104 cells/well) and incubated overnight to allow cell
Fig. 1. Schematic representation of PLGA(PTX), BN-PLGA(PTX) and 177Lu-BN-PLGA(PTX) nanosystems.
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attachment. Then, the medium was removed and 50 μL of each treat-
ment and 200 μL of RPMI medium were placed in each well. The via-
bility was evaluated after removing the medium at 72 h (37 °C, 5% CO2
and 85% humidity).
2.10.4. Study of the synergistic therapeutic effect
To evaluate the chemotherapeutic (PTX) and radiotherapeutic
(177Lu) synergistic effect of the radiolabeled nanosystem on cell viabi-
lity, 1× 104 cells/well were exposed to 177Lu-BN-PLGA(PTX) or un-
labeled (BN-PLGA(PTX) nanosystems (30 μM in terms of PTX content).
The viability was evaluated through the XTT protocol at 24, 48 and
72 h.
2.10.5. Estimation of radiation-absorbed doses to the MDA-MB-231cell
nucleus
To estimate the radiation-absorbed doses to the MDA-MB-231 cell
nucleus, the following equation was used:
= × + ×D N DF N DF( ) ( )N Source M N M C N C (3)
where DN←Source represents the mean absorbed dose to the nucleus from
source regions (membrane and cytoplasm) and NM and NC are the total
number of nuclear disintegrations that occurred in the membrane and
cytoplasm. DFN←M and DFN←C denote the dose factors specific for
177Lu, from membrane and cytoplasm regions to the nucleus config-
uration. The dose factor geometries were obtained from the S values
reported by Goddu and Budinger (cell radius= 10 μm, nucleus
radius= 5 μm) [19].
2.10.6. Hemocompatibility
For medical devices projected for direct or indirect blood exposure,
hemocompatibility studies are required [20]. In this work, the potential
of the nanosystems to disrupt red blood cells (RBC) was assessed by the
hemolytic assay.
The hemolytic assay was performed in agreement with the standard
ISO 10 993-4. Briefly, 200 μL of each treatment (n=3) was placed in
contact with 5% human RBC. Trials were immediately incubated at
37 °C for 1 h with negative (isotonic saline) and positive controls (dis-
tilled water). Optical density (OD) produced in each treatment was
measured at 415 nm (Lambda Bio, Perkin Elmer, USA). The percentage






2.11. In vivo studies
In vivo studies in mice were carried out according to the Official
Mexican Norm 062-ZOO-1999. Athymic female mice (6–7 weeks of age)
were identified and transferred inside plastic cases, kept at a constant
temperature, humidity, 12:12 light:dark periods and fed ad libitum.
2.11.1. Tumor induction
a) Tumor model for single-photon emission computed tomography
(SPECT/CT) imaging and biodistribution studies
Athimic female mice received an intravenous (caudal vein, for
pulmonary tumor model) or subcutaneous (upper back, for sub-
cutaneous tumor model) inoculation of 1×106 MDA-MB-231 cancer
cells suspended in 0.1mL of phosphate-buffered saline, and 2weeks
after inoculation the animals were used for the imaging or biodis-
tribution studies, respectively.
b) Tumor model for FDG-PET/CT (18F-deoxyglucose-positron emission
tomography/computed tomography) and SUV (standard uptake
value) calculation.
To assess the extent of tumoral progression under exposure to dif-
ferent treatments, breast tumors (MDA-MB-231 cells, 1× 106 in PBS)
were subcutaneously inoculated on the upper back of 16 female
athymic mice (5–6weeks of age) and the inoculation site was observed
for the development of a tumor. Mice survival and size tumor were
monitored for 12 days.
2.11.2. Micro SPECT-CT imaging
To verify the in vivo nano-radiosystem retention in induced pul-
monary tumors, SPECT-CT images were acquired using a micro-SPECT/
CT scanner (Albira, ONCOVISION; Gem Imaging S.A., Valencia, Spain)
72 h after intravenous 177Lu-BN-PLGA(PTX) administration (5MBq in
0.1 mL PBS). Mice under 2% isoflurane anesthesia were placed in the
prone position and imaging was performed. The micro-SPECT field of
view was 60mm; a symmetric 20% window was set at 140 keV, and
pinhole collimators were used to acquire a three-dimensional SPECT
image with a total of 64 projections of 30 s each over 360°. The image
dataset was then reconstructed using the ordered-subset expectation
maximization algorithm with the standard mode parameter, as pro-
vided by the manufacturer. CT parameters were 35 kV sure voltage,
700 μA current and 600 micro-CT projections.
2.11.3. Biodistribution
The subcutaneous tumor model animals received 5MBq in 0.1 mL of
177Lu-BN-PLGA(PTX). Seventy-two hours after injection, the mice were
euthanized and the blood and main organs were removed and placed
into pre-weighed plastic test tubes. The radioactivity was measured in a
well-type scintillation Na(Tl) detector along with two aliquots of stan-
dards (representing 100% of injected activity) and expressed as per-
centages of the injected dose per gram (%ID/g) or per organ (%ID/
organ).
2.11.4. FDG-PET/CT imaging
To assess the tumoral progression (Section 2.11.1), the female mice
with MDA-MB-231 tumors were randomly separated into 4 groups. The
mean volume of the tumors was 0.119 ± 0.035 cm3, calculated as
V=π/6 ∗ L ∗ a2. The length (L) and width (a) were measured with
Vernier calipers [21]. Mice were anesthetized with isofluorane 2% and
administered intratumorally with each treatment as follows: a) 3MBq
of 177Lu-BN-PLGA(PTX), b) 3MBq of 177Lu-BN-PLGA and the equivalent
mass of c) PLGA(PTX) or d) PLGA as the control.
After 8 days of treatment, images were acquired on a micro-PET/CT
scanner (Albira, ONCOVISION, Spain) and the tumor metabolic activity
was measured through the Standardized Uptake Value (SUV) of 18F-
Deoxyglucose (FDG). The mice were administered with 70–100 μL
(3–4MBq) of FDG on the tail vein under anesthesia. After 1 h, whole
body images were acquired in a micro-PET/CT, and the Standard
Uptake Value (SUV) was calculated using PMOD Data Analysis soft-
ware.
Finally, the mice were euthanized since the control tumor size was
higher than 1.83mm3.
2.11.5. Tumor radiation absorbed dose estimation
The radiation-absorbed dose (the energy deposited by ionizing ra-
diation per unit of mass expressed in Gy) of 177Lu-BN-PLGA(PTX) and
177Lu-BN-PLGA to tumor was calculated according to the following
expressions:









=D N DFtumor tumor tumor tumor tumor (6)
where N= total number of disintegration in the tumor, t1= 0 day and
t2= 8 day post-treatment, λ= ln2/t1/2 or (ln2/6.7d), A0= initial ad-
ministered Lu-177 activity (Bq), Dtumor tumor =mean absorbed dose to
tumor from tumor, and DF is the dose factor for Lu-177.
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The N value was introduced to Organ Level Internal Dose
Assessment (OLINDA) code, (which provides conversion factors (DF))
to estimate the radiation-absorbed dose (Dtumor tumor) delivered by Lu-
177 administered with each treatment.
2.12. Statistical analysis
Differences in cell uptake between unblocked and blocked receptors
were evaluated with the Student t-test. The cytotoxicity results were
estimated by a two-sided ANOVA using OriginLab and GraphPrisma
software, setting the statistical significance at p < 0.05.
3. Results and discussion
The application of polymeric nanoparticles for PTX release, GRPr
targeting and targeted radiotherapy with 177Lu has been studied in this
research to achieve a dual therapeutic effect on MDA-MB-231 breast
cancer cells.
3.1. Preparation of PLGA and PLGA(PTX) nanoparticles
In this research, minor modifications in the emulsion-solvent
method [14] allowed us to obtain both the free-drug PLGA and pacli-
taxel-loaded PLGA nanoparticles. The hydrophobic hydrocarbon chains
from the lactide moieties in PLGA enabled the interaction with hy-
drophobic PTX, allowing thermodynamic folding and the consequent
nanoparticle formation [3].
Scanning Electron Microscopy and Transmission Electron
Microscopy micrographs (Fig.2) showed that the designed nanosystems
presented a well-shaped spherical form. The morphology was not
modified by PTX incorporation or the grafted BN. All nanoparticle
systems showed a hydrodynamic diameter< 200 nm (by DLS) and a
monomodal distribution. A narrow polydispersity was observed for
PLGA and PLGA(PTX) systems (Table 1). However, the PDI increased as
a result of functionalization with BN (0.2896 and 0.2987). In general, a
PDI smaller than 0.2 is considered as a narrow-size distribution [22].
Specifically, the size range was 104 nm to 201 nm for PLGA and 109 nm
to 213 nm for PLGA(PTX), without significant differences (p < 0.05).
Negative zeta potential of PLGA nanoparticles (−18.9mV) is at-
tributed to the carboxylate groups on the nanoparticle surface. In
PLGA(PTX), the Z potential remained unchanged in charge, which
could mean that the paclitaxel remained entrapped in the nano-
particles, in agreement with the results of chemical characterization.
3.2. Conjugation of bombesin to PLGA or PLGA(PTX)
Bombesin was conjugated to the PLGA or PLGA(PTX) by the cou-
pling peptide reaction, using HATU as the activator molecule. The at-
tachment of BN onto the nanoparticle surface did not affect the trans-
lational diffusion coefficient, which can be understood as the
maintenance in equivalent hydrodynamic diameter, keeping apparent
nanoparticle sizes. However, the zeta potential showed a significant
decrease from −18.9mV to -11mV in BN-PLGA and from −19.0mV to
−12.3mV in BN-PLGA(PTX). The reduction in Z potential values sug-
gests that the peptide interaction and arrangement on the nanoparticle
surface originate changes in the electrostatic environment surrounding
the nanoparticle. The positive amine, amide bonds and neutral hydro-
carbon chains of Lys1Lys3(DOTA)-BN could contribute to the reduction
Fig. 2. Representative TEM micrograph of a) PLGA, b) PLGA(PTX), c) BN-PLGA(PTX) and d) SEM image of PLGA NPs.
Table 1
Physicochemical characterization of nanoparticles.
Nanoparticle Size (nm) Polydispersity index
(PDI)
Z potential (mV)
PLGA 152.90 ± 48.56 0.1977 −18.9
PLGA(PTX) 161.23 ± 52.27 0.1914 −19.0
BN-PLGA 156.19 ± 54.18 0.2896 −11.0
BN-PLGA(PTX) 163.54 ± 33.25 0.2987 −12.3
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of the zeta potential. BN conjugation efficiency, indirectly measured by
HPLC, was calculated to be>97%. The measured diameters of the
nanoparticles could be affected by shrinking producing a structure
modification. It is possible that NPs become highly porous, which could
contribute to the changes observed in the nanoparticle average size
evaluated by SEM with respect to DLS results, although without sta-
tistically significant differences.
In terms of physicochemical properties, a significant accumulation
of bombesin-grafted nanoparticles on tumor tissue is expected by two
different mechanisms, the enhanced permeability and retention (EPR)
effect and active targeting thorough GRP cell receptors. Then, in the
neovasculature of tumor, the characteristic fenestrations of
200–780 nm would allow the extravasation of 177Lu-BN-PLGA(PTX)
(200 nm) in the tumoral acid microenvironment, with the consequent
PTX delivery and cancer cell internalization by simple PTX diffusion
due to its small molecule size and lipophilic properties (< 1000 Da).
177Lu-BN-PLGA(PTX) could also be actively incorporated into the cell
by different endocytic pathways attributed to the specific recognition
by the GRPr [12,23,24].
3.3. Radiolabeling efficiency and radiochemical purity
Radiolabeling efficiency of the nanosystems was determined by ul-
tracentrifugation (45%), and after purification, radiochemical purity
(evaluated by ITLC) was 99 ± 1%.
3.4. Infrared spectroscopy
The PLGA nanoparticle spectrum was consistent with that pre-
viously reported [11,14]. Characteristic vibrational modes were ob-
served, such as (CeH)υ from the co-polymer carbon skeletal between
2942 cm−1 and 2918 cm−1, (C]O)υ vibration of the ester group at
1752 cm−1, (CeH)δ from bonds between monomeric units of lactide-
glycolide (L-G: 1376 cm−1), glycolide-glycolide (G-G: 1425 cm-1) and
lactide-lactide (L-L: 1453 cm−1) and (CeO)υ, (OeH)δ and (OeH)υ as
evidence of stabilization with PVA (Fig. 3c).
IR analysis of the PTX was consistent with previous reports [25].
Briefly, the spectrum showed stretching (eNeH) vibrations character-
ized by a broad and asymmetric band centered at 3442 cm−1. The band
found at 2945 cm−1 was assigned to (eCeH) from asymmetric and
symmetric stretching vibrations. The amide I region mainly associated
with a (C]O) stretching vibration was identified at 1732 cm−1,
whereas (CeN) stretching was found at 1274 cm−1. Aromatic hydro-
carbons were identified by characteristic absorption bands in the region
near to 1645 cm−1 and 1500–1400 cm−1, produced by carbon‑carbon
stretching vibrations in the aromatic ring. The bands in the
1250–1000 cm−1 region were assigned to CeH in-plane bending, and
finally, CeH stretching above 3000 cm−1 was also identified (Fig. 3a).
The IR spectrum corresponding to paclitaxel-loaded PLGA nano-
particles (Fig. 3d) showed no difference with regard to the empty na-
noparticle spectrum. These spectra did not display the characteristic
intense bands from free PTX; they may have been masked by the bands
produced by the polymer. The possible absence of chemical interaction
between the polymer and drug may indicate a complete encapsulation
of paclitaxel into the nanoparticles [26,27].
The spectra of pure Lys1Lys3(DOTA)BN (Fig. 3b) showed char-
acteristic peaks at 3283, 1646 and 1533 cm−1, corresponding to eNH
stretching, C]O stretching (Amide I) and eCN (amide II), as previously
reported [28].
BN-conjugated nanoparticles (BN-PLGA(PTX) showed the con-
tribution of characteristic vibrations from each component. The peaks
at 1666 cm−1 and 1536 cm−1 on BN-PLGA(PTX) from amide stretching
vibrations makes the presence of BN in PLGA nanoparticles evident
(Fig. 3e).
3.5. Encapsulation efficiency (EE) and drug loading (DL)
The efficiency of hydrophobic paclitaxel encapsulation in BN-
PLGA(PTX) was calculated by subtracting the free drug measured in a
filtered solution from the total amount used to prepare the nano-
particles. HPLC analysis was carried out at λmax= 227 nm, using a
standard curve related to the absorption and PTX concentration
(6.0–300.0 μg/mL r2= 0.997). The efficiency of drug encapsulation
was 92.8% ± 3.6, in agreement with similar reports [26,29,30]; and
drug loading was 1.13 ± 0.13%. It was observed that loading capacity
decreases in function of the size; thus high concentration of nano-
particles may be needed for therapeutic efficacy.
3.6. In vitro release
To evaluate the controlled release capacity of PTX from BN-
PLGA(PTX), the nanosystem was evaluated in simulated physiological
pH (7.4) and acidic microenvironment tumor conditions (pH 5.3). The
cumulative release percentage of PTX is shown in Fig. 4.
The kinetic drug release profiles exhibited biphasic patterns with
release during the first 25 h of 66.8% and 63.7% at pH 5.3 and 7.4,
Fig. 3. Infrared spectra of a) paclitaxel, b) Lys1Lys3(DOTA)Bombesin, c) PLGA
nanoparticles d) PLGA(PTX) nanoparticles and e) BN-PLGA(PTX) nanoparticles.
Fig. 4. In vitro release of PTX from paclitaxel-loaded PLGA nanoparticles in PBS
(pH 5.3 and 7.4) fitted to the non-linear Hill model.
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respectively, followed by a slow and continuous release during 15 days.
Significant differences (p < 0.05) dependent on pH were observed, the
maximum amount of drug release was reached at pH 5.3 (84.8%),
whereas at pH 7.4 the maximum release was 77.1% of the total en-
trapped drug. As it is known, the higher release at pH 5.3 is attributed
to the effect of hydrolysis and degradation of the polymer [31].
Therefore, paclitaxel release from BN-PLGA(PTX) in the acidic tumor
microenvironment may have an improvement over anticancer drug
delivery. The presented results support the proposal that loading hy-
drophobic molecules such as PTX on PLGA nanoparticles could enhance
their accumulation on tumor tissues with the consequent decrease of
the adverse effects produced by the drug.
3.7. In vitro uptake study
The therapeutic efficiency of paclitaxel-loaded PLGA depends on the
nanosystem cell uptake, their intracellular distribution, and the release
from internalized nanoparticles.
As previously reported, GRPr is overexpressed in several breast
cancer cell lines such as MDA-MB-231 and T47D [16,17,32]. Cell up-
take was evaluated comparing the behavior of 177Lu-BN-PLGA(PTX)
and 177Lu-BN as a monomeric system. The results showed a specific
uptake of 177Lu-BN-PLGA(PTX) de 4.58 ± 0.42%, which was sig-
nificantly reduced (p < 0.05) when GRP receptors of MDA-MB-231
cells were blocked by pre-incubation (10min before treatment ex-
posure) with free Lys1Lys3BN peptide (Fig. 5a). This evidence suggests
that the active targeting was achieved due to the PLGA surface mod-
ification with BN.
The specific uptake of 177Lu-BN was also confirmed. It was the
highest uptake value observed (8.20 ± 0.49%), which was effectively
diminished (1.6 ± 0.26%) when receptors were previously blocked in
the presence of 5.7 μM Lys1Lys3(DOTA)-BN (10min of pre-incubation)
(Fig. 5a). While the free PTX does not require a ligand-receptor inter-
action to mediate endocytosis, 177Lu-BN-PLGA(PTX) is introduced into
the cell through several mechanisms. It has been demonstrated that
nanoparticle systems conjugated to bombesin interact specifically with
GRP receptors, increasing the ligand internalization by clathrin-medi-
ated endocytosis, and thus allow a suitable delivery of paclitaxel into
MDA-MB-231 cells; this enables the system to produce a higher level of
toxicity [22,33].
Therefore, 177Lu-BN-PLGA(PTX) nanosystems exhibited cellular
uptake based on receptor-mediated endocytosis attributed to the in-
teraction of BN with the GRP receptor. The active targeting was
achieved by modifying the PLGA with BN. However, further informa-
tion on the kinetics of internalization is needed to correlate the cargo
delivery profile to understand the in vitro behavior.
3.8. Estimation of radiation-absorbed doses to the MDA-MB-231cell
nucleus
Based on the uptake (radioactivity in the membrane) and inter-
nalization (radioactivity in cytoplasm) results as well as 177Lu decay
properties, the biokinetic models of 177Lu-BN-PLGA(PTX) and 177Lu-BN
were obtained and the radiation absorbed doses calculated for MDA-
MB-231 cells.
The total absorbed dose produced to the cell nuclei by 177Lu-BN at
72 h was 0.659 Gy, 1.6 times higher than that produced by 177Lu-BN-
PLGA(PTX) (0.400 Gy, Table 2). All the estimated doses delivered by
each treatment were lower than 1 Gy. In this regard, it is reported that a
dose of 100 Gy is required to destroy cell function in non-proliferating
systems, and the mean lethal dose for loss of proliferative capacity is
about 2 Gy [34]. Moreover, a recent study demonstrated that the ra-
diation-absorbed dose in the nucleus of 4.8 Gy on lymphoma cells in-
duced DNA damage and produced an important increase in the apop-
totic cell population (98%), mostly in late-stage (irreversible) apoptosis
[35]. As previously mentioned, our intention during the cytotoxicity
evaluation was to evaluate differences between 177Lu treatments
without inducing cell death, which is why doses below 2 Gy were used.
However, for the study of the synergistic therapeutic effect, doses of
8 Gy were applied (Table 2).
Fig. 5. a) 177Lu-BN and 177Lu-BN-PLGA(PTX) cellular uptake. Pre-incubated MDA-MB-231 cells with Lys1Lys3-DOTA-BN (blocked receptors) and without
Lys1Lys3(DOTA)-BN pre-incubation (unblocked receptors) and b) internalization with regard to total uptake.
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3.9. In vitro cytotoxicity
Fig. 6 shows that 177Lu-BN-PLGA(PTX) caused a significant decrease
in cell viability when compared to BN-PLGA(PTX), 177Lu-BN or PTX.
At 72 h of treatment, 0.40 Gy of radiation absorbed dose was de-
posited into the nucleus of an MDA-MB-231 cell treated with 177Lu-BN-
PLGA(PTX). At this time point, the viability decreased to
78.9 ± 2.61%, which was significantly different compared to BN-
PLGA (94.1 ± 0.5%, p < 0.001), PLGA (92.2 ± 3.2%, p < 0.001),
PTX (85.0 ± 1.8%, p < 0.001) and 177Lu-BN (87.4 ± 3.3%,
p < 0.001), even when in the latter, the radiation absorbed dose was
0.659 Gy (Table 2).
Since the in vitro binding assay demonstrated specific uptake at
45min of treatment exposure, the uptake and consequent observed cell
death without a significant difference (p < 0.05) for the PLGA(PTX)
group (90.56 ± 7.30%), compared with BN-PLGA(PTX)
(84.84 ± 2.52%), was attributed to the delivered PTX as a result of the
unspecific invagination produced by the weak cooperative interactions
between NPs and cells. Moreover, it was expected that the endocytic
pathways having low efficiency were favored by the exposition time
(72 h) for both treatments. [24,36].
After 72 h, the cell viability produced by 1.5 μM of free PTX
(85.0 ± 1.8%) was significantly different (p < 0.001) when compared
with the survival rate (78.9 ± 2.61%) produced by 177Lu-BN-
PLGA(PTX). At this time point, an important amount of PTX (74%) had
been released, contributing to the cell toxicity (Fig. 3). These results are
expected since a concentration of 15 μM of PTX is required to produce
significant cell death [18]. Furthermore, the encapsulation of PTX on
PLGA nanoparticles enhances the cytotoxic effect (Fig. 6).
In terms of radiosensitization, nanoparticles encapsulating chemical
compounds have been proposed to enhance the response to radiation
[37]. In Fig. 6, the synergistic effect between chemotherapy and
radiotherapy is observed. The high decrease in viability produced by
177Lu-BN-PLGA(PTX) between 24 and 48 h is mainly attributed to the
radiosensitization effect produced by PTX.
The synergistic effect of chemotherapy and radiotherapy produced
by the 177Lu-BN-PLGA(PTX) nanosystem was evident when doses of
PTX=30 μM and radiation-absorbed doses of 8 Gy were used. As can
be observed in Fig. 7, the greater cytotoxic effect for the radiolabeled
nanosystem was observed between 24 and 72 h (highest slope) given
that, at this time, a significant PTX and radiation dose delivery had
occurred.
3.10. Hemocompatibility
The non-hemolytic behavior of the 177Lu-BN-PLGA(PTX) supports
its suitability for intravenous administration (0.97 ± 0.05%). The
systems can be classified as non-hemolytic materials, based on the he-
molysis value being lower than 2% [38].
3.11. In vivo studies
Fig. 8a shows a representative SPECT image of a mouse with an
MDA-MB-231 pulmonary tumor model. The tumor-to-blood ratio re-
veals suitable contrast, with a significant accumulation of 177Lu-BN-
PLGA(PTX) nanomedicine in tumor tissue after 72 h of injection with a
standard uptake value (SUV) of 3. The ex vivo biodistribution results of
177Lu-BN-PLGA(PTX) also showed a high tumor uptake in MDA-MB-231
lesions (Fig. 8b). However, future studies are required to obtain a
complete 177Lu-BN-PLGA(PTX) biokinetic profile for the in vivo
Table 2
Biokinetic model and radiation absorbed doses produced by 0.5 Bq/cell of 177Lu-radiopharmaceuticals to the MDA-MB-231 cancer cell nuclei within 72 h.










Total dose to cell nuclei (Gy)
177Lu-BN-PLGA(PTX) 0.400
Membrane A(t)= 0.089e−3.96t+3.730e−0.009t+0.780e−0.007t 8712 0.332
Cytoplasm A(t)= 9.880e−10.004t+0.159e−0.008t+0.337e−0.008t 1004 0.075
177Lu-BN 0.659
Membrane A(t)= 0.422e−25.404t+6.25e−0.008t+1.98e−0.010t 15,912 0.594
Cytoplasm A(t)= 0.439e−28.704t+0.132e−0.012t+0.337e−0.008t 904 0.065
Fig. 6. Effect on cell viability after exposure of MDA-MB-231 cells to sublethal
doses of paclitaxel (1.5 μM) and 177Lu radiation doses (< 1Gy) in different
nanosystems.
Fig. 7. Effect on MDA-MB-231cell viability after exposure to 177Lu-BN-
PLGA(PTX), compared to BN-PLGA(PTX). PTX=30 μM, radiation dose=8 Gy
at 72 h.
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absorbed dose assessment and for the evaluation of its therapeutic ef-
ficacy in different breast cancer models.
Since the micro-PET/CT imaging at the end of the in vivo studies
showed a tumor volume for the mice control group of 1.83 ± 0.54 cm3,
the combination of targeted radiotherapy (provided by 177Lu-BN) and
chemotherapy (provided by PTX) resulted in the highest inhibition of
breast tumor growth for the mice administered with 177Lu-BN-
PLGA(PTX), which reached the lowest tumor proliferation
(0.136 ± 0.04 cm3). The group exposed to 177Lu-BN-PLGA produced a
final tumor of 0.654 ± 0.202 cm3 and the PLGA(PTX) group produced
a tumoral volume of 0.216 ± 0.072 cm3. Therefore, the response to
treatment was in this order: 177Lu-BN-
PLGA(PTX) > PLGA(PTX) > 177Lu-BN-PLGA>PLGA (control).
The SUV data, related directly to the metabolic activity, were
42.43 ± 5.54, 24.31 ± 4.51, 14.74 ± 2.92 and 8.10 ± 1.06 for the
control group, 177Lu-BN-PLGA, PLGA(PTX), 177Lu-BN-PLGA(PTX), re-
spectively. Even though the average radiation-absorbed dose of 177Lu-
BN-PLGA(PTX) and 177Lu-BN-PLGA delivered to the tumor was the
same (36.9 ± 7.01 Gy), and this dose corresponds to that usually ap-
plied in radiotherapy treatments to breast cancer patients, the 177Lu-
BN-PLGA(PTX) conjugated showed the lowest tumoral metabolic ac-
tivity (lowest SUV) and almost complete inhibition of the tumor pro-
gression (lowest tumoral volume). These results corroborate the sy-
nergistic effect between radiation therapy and chemotherapy in a single
nanosystem (Fig. 9).
4. Conclusions
177Lu-BN-PLGA(PTX) nanoparticles are suitable systems for the bi-
modal therapy of breast cancer due to the synergistic effect on cell
viability of the 177Lu radiation dose delivery and the controlled release
of paclitaxel. The radiolabeling of BN-PLGA(PTX) with Lu-177 allows
for the acquisition of GRPr overexpression images in breast cancer tu-
mors, making the monitoring of disease progression possible. Further
studies are needed to determine the therapeutic efficacy of 177Lu-BN-
PLGA(PTX) in different breast cancer preclinical models.
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